Compare HRI & DYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HRI | DYN |
|---|---|---|
| Founded | 1965 | 1984 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Misc Corporate Leasing Services | Medicinal Chemicals and Botanical Products |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.7B | 4.8B |
| IPO Year | 2006 | 2020 |
| Metric | HRI | DYN |
|---|---|---|
| Price | $165.16 | $25.88 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 14 |
| Target Price | ★ $162.33 | $37.00 |
| AVG Volume (30 Days) | 464.7K | ★ 2.5M |
| Earning Date | 04-28-2026 | 05-04-2026 |
| Dividend Yield | ★ 2.13% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $4,376,000,000.00 | N/A |
| Revenue This Year | $10.12 | N/A |
| Revenue Next Year | $6.16 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 22.65 | N/A |
| 52 Week Low | $88.45 | $11.92 |
| 52 Week High | $188.35 | $27.31 |
| Indicator | HRI | DYN |
|---|---|---|
| Relative Strength Index (RSI) | 54.27 | 58.62 |
| Support Level | $150.81 | $16.45 |
| Resistance Level | $172.56 | $26.96 |
| Average True Range (ATR) | 6.59 | 0.96 |
| MACD | -0.60 | -0.14 |
| Stochastic Oscillator | 62.79 | 67.04 |
Herc Holdings is an equipment rental company that was spun out of Hertz Global in 2016. It is currently the third-largest player in North America, after United Rentals and Sunbelt Rentals, with an approximate 6% market share pro forma for its 2025 acquisition of H&E Equipment Services. It serves a similar mix of companies to its peers (industrial, commercial, and residential construction) from its 450 locations targeting the top 100 metropolitan markets in the US. Herc's rental fleet of approximately $7 billion is also similar in composition to its peer group in terms of equipment offered. The company is also pursuing diversification by bundling and increasing specialty solutions for its customer base. Herc's portfolio skews toward local customers versus national accounts (60%/40%).
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease being treated, a linker, and an antigen-binding fragment that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.